FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2095914632> ?p ?o ?g. }

• W2095914632 endingPage "755" @default.
• W2095914632 startingPage "750" @default.
• W2095914632 abstract "We investigated the value of the neutrophil–lymphocyte ratio (NLR) in patients with CRPC treated with chemotherapy in the phase III TROPIC trial. High NLR was associated with worse survival (OS) and reduced PSA and radiographic response. Conversion (high to low NLR) was associated with improved OS. NLR can be a useful biomarker to assess prognosis and response to treatment.BackgroundThe neutrophil–lymphocyte ratio (NLR), proposed as an indicator of cancer-related inflammation, has known prognostic value in prostate cancer. We examine its association with survival (OS) and response in patients treated with second-line chemotherapy.MethodsWe analysed patients with metastatic castration-resistant prostate cancer (mCRPC) treated in the TROPIC trial, evaluating cabazitaxel versus mitoxantrone. Cox regression models were used to investigate the association of baseline NLR (BLNLR) with OS and the significance of a change in NLR count with treatment. Logistic regression models were used to determine the association of BLNLR counts with prostate specific antigen (PSA) and RECIST responses. The optimal NLR cut-off was established based on the concordance index of different values.ResultsData from 755, 654 and 405 patients was available for OS, PSA and RECIST response analysis respectively. Median OS was 14.0 months [95% confidence interval (CI) 13.2–14.8]. Median NLR was 2.9 (IQR: 1.9–5.1). BLNLR was associated with survival (HR 1.5, 95% CI 1.1–2.1,P = 0.011) in multivariable analysis (MVA) independently of variables included in the Halabi nomogram, treatment arm and corticosteroid use. The optimal cut-off for a dichotomous NLR was selected at 3.0 based on its higher c-index related to survival. BLNLR ≥3.0 was associated with lower PSA response (40.1% versus 59.9%;P < 0.001) and RECIST response (7.7% versus 15.6%,P = 0.022) in MVA. Conversion from high (≥3) to low (<3) NLR was associated with improved survival (HR 0.66; 95% CI 0.51–0.85;P = 0.001) and higher PSA response rates (66.4% versus 33.6%;P = 0.000). Use of corticosteroids at baseline did not modify the association between NLR and survival.ConclusionsNLR is a valid prognostic biomarker in CRPC and is associated with survival, PSA and RECIST responses in patients treated with second-line chemotherapy. Changes in NLR counts with treatment may indicate benefit. NLR prognostic value is independent of prior use of corticosteroids.ClinicalTrials.govNCT00417079." @default.
• W2095914632 created "2016-06-24" @default.
• W2095914632 creator A5014912122 @default.
• W2095914632 creator A5032324017 @default.
• W2095914632 creator A5034586479 @default.
• W2095914632 creator A5048283327 @default.
• W2095914632 creator A5050901329 @default.
• W2095914632 creator A5073246821 @default.
• W2095914632 creator A5079652931 @default.
• W2095914632 creator A5080919044 @default.
• W2095914632 creator A5081930790 @default.
• W2095914632 creator A5088696108 @default.
• W2095914632 date "2015-04-01" @default.
• W2095914632 modified "2023-10-16" @default.
• W2095914632 title "Baseline neutrophil–lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use" @default.
• W2095914632 cites W1968545383 @default.
• W2095914632 cites W1982906652 @default.
• W2095914632 cites W2033476800 @default.
• W2095914632 cites W2071433338 @default.
• W2095914632 cites W2096910745 @default.
• W2095914632 cites W2103959341 @default.
• W2095914632 cites W2117692326 @default.
• W2095914632 cites W2119034557 @default.
• W2095914632 cites W2120579447 @default.
• W2095914632 cites W2123526148 @default.
• W2095914632 cites W2130669171 @default.
• W2095914632 cites W2148998801 @default.
• W2095914632 cites W2150418305 @default.
• W2095914632 cites W2153641732 @default.
• W2095914632 cites W2154361786 @default.
• W2095914632 cites W2167331614 @default.
• W2095914632 doi "https://doi.org/10.1093/annonc/mdu587" @default.
• W2095914632 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25538172" @default.
• W2095914632 hasPublicationYear "2015" @default.
• W2095914632 type Work @default.
• W2095914632 sameAs 2095914632 @default.
• W2095914632 citedByCount "160" @default.
• W2095914632 countsByYear W20959146322015 @default.
• W2095914632 countsByYear W20959146322016 @default.
• W2095914632 countsByYear W20959146322017 @default.
• W2095914632 countsByYear W20959146322018 @default.
• W2095914632 countsByYear W20959146322019 @default.
• W2095914632 countsByYear W20959146322020 @default.
• W2095914632 countsByYear W20959146322021 @default.
• W2095914632 countsByYear W20959146322022 @default.
• W2095914632 countsByYear W20959146322023 @default.
• W2095914632 crossrefType "journal-article" @default.
• W2095914632 hasAuthorship W2095914632A5014912122 @default.
• W2095914632 hasAuthorship W2095914632A5032324017 @default.
• W2095914632 hasAuthorship W2095914632A5034586479 @default.
• W2095914632 hasAuthorship W2095914632A5048283327 @default.
• W2095914632 hasAuthorship W2095914632A5050901329 @default.
• W2095914632 hasAuthorship W2095914632A5073246821 @default.
• W2095914632 hasAuthorship W2095914632A5079652931 @default.
• W2095914632 hasAuthorship W2095914632A5080919044 @default.
• W2095914632 hasAuthorship W2095914632A5081930790 @default.
• W2095914632 hasAuthorship W2095914632A5088696108 @default.
• W2095914632 hasBestOaLocation W20959146321 @default.
• W2095914632 hasConcept C121608353 @default.
• W2095914632 hasConcept C126322002 @default.
• W2095914632 hasConcept C143998085 @default.
• W2095914632 hasConcept C207103383 @default.
• W2095914632 hasConcept C2776694085 @default.
• W2095914632 hasConcept C2777761686 @default.
• W2095914632 hasConcept C2777899217 @default.
• W2095914632 hasConcept C2778336483 @default.
• W2095914632 hasConcept C2778963024 @default.
• W2095914632 hasConcept C2778971682 @default.
• W2095914632 hasConcept C2780192828 @default.
• W2095914632 hasConcept C2781406297 @default.
• W2095914632 hasConcept C34626388 @default.
• W2095914632 hasConcept C44249647 @default.
• W2095914632 hasConcept C50382708 @default.
• W2095914632 hasConcept C71924100 @default.
• W2095914632 hasConceptScore W2095914632C121608353 @default.
• W2095914632 hasConceptScore W2095914632C126322002 @default.
• W2095914632 hasConceptScore W2095914632C143998085 @default.
• W2095914632 hasConceptScore W2095914632C207103383 @default.
• W2095914632 hasConceptScore W2095914632C2776694085 @default.
• W2095914632 hasConceptScore W2095914632C2777761686 @default.
• W2095914632 hasConceptScore W2095914632C2777899217 @default.
• W2095914632 hasConceptScore W2095914632C2778336483 @default.
• W2095914632 hasConceptScore W2095914632C2778963024 @default.
• W2095914632 hasConceptScore W2095914632C2778971682 @default.
• W2095914632 hasConceptScore W2095914632C2780192828 @default.
• W2095914632 hasConceptScore W2095914632C2781406297 @default.
• W2095914632 hasConceptScore W2095914632C34626388 @default.
• W2095914632 hasConceptScore W2095914632C44249647 @default.
• W2095914632 hasConceptScore W2095914632C50382708 @default.
• W2095914632 hasConceptScore W2095914632C71924100 @default.
• W2095914632 hasIssue "4" @default.
• W2095914632 hasLocation W20959146321 @default.
• W2095914632 hasLocation W20959146322 @default.
• W2095914632 hasOpenAccess W2095914632 @default.
• W2095914632 hasPrimaryLocation W20959146321 @default.
• W2095914632 hasRelatedWork W1980998207 @default.
• W2095914632 hasRelatedWork W2299690226 @default.
• W2095914632 hasRelatedWork W2343768426 @default.

• next